July 21, 2017 / 11:49 AM / a month ago

Janssen-Cilag's HIV drug gets EU regulatory panel's nod

(Reuters) - A European regulatory panel recommended granting approval to a treatment for HIV infection developed by Janssen-Cilag International, a unit of U.S. drugmaker Johnson & Johnson.

The drug, Symtuza, is a combination of four active substances darunavir, cobicistat, emtricitabine and tenofovir alafenamide. (bit.ly/2gPiBAD)

The human immunodeficiency virus (HIV), which causes AIDS, interferes with the body's ability to fight infections.

More than 35 million people have died from AIDS-related illnesses and an estimated 78 million have become infected with HIV, since the disease surfaced 36 years ago.

Reporting by Rahul B in Bengaluru; Editing by Saumyadeb Chakrabarty

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below